Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spyre Therapeutics Inc SYRE

Healthcare Biotechnology
Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and... see more

Recent & Breaking News (NDAQ:SYRE)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Accesswire November 19, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

PR Newswire November 18, 2024

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

PR Newswire November 18, 2024

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

PR Newswire November 12, 2024

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

PR Newswire November 11, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire November 7, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire November 1, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

PR Newswire October 30, 2024

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

PR Newswire October 14, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire October 4, 2024

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

PR Newswire October 1, 2024

Spyre Therapeutics to Participate in Upcoming Investor Conference

PR Newswire September 10, 2024

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 7, 2024

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

GlobeNewswire July 18, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

PR Newswire June 18, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire June 3, 2024

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

PR Newswire May 29, 2024

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

PR Newswire May 15, 2024

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 9, 2024

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire May 3, 2024